Nicole M De Jesus1, Lianguo Wang2, Johnny Lai1, Robert R Rigor2, Samantha D Francis Stuart2, Donald M Bers2, Merry L Lindsey3, Crystal M Ripplinger4. 1. Department of Biomedical Engineering, School of Engineering, and. 2. Department of Pharmacology, School of Medicine, University of California, Davis, Davis, California. 3. Department of Physiology and Biophysics, Mississippi Center for Heart Research, University of Mississippi Medical Center, Jackson, Mississippi. 4. Department of Pharmacology, School of Medicine, University of California, Davis, Davis, California. Electronic address: cripplinger@ucdavis.edu.
Abstract
BACKGROUND: Interleukin 1β (IL-1β) is a key regulator of the inflammatory response after myocardial infarction (MI) by modulating immune cell recruitment, cytokine production, and extracellular matrix turnover. Elevated levels of IL-1β are associated with adverse remodeling, and inhibition of IL-1 signaling after MI results in improved contractile function. OBJECTIVE: The goal of this study was to determine whether IL-1 signaling also contributes to post-MI arrhythmogenesis. METHODS: MI was created in 2 murine models of elevated inflammation: atherosclerotic on the Western diet or wild-type with a subseptic dose of lipopolysaccharide. The role of IL-1β was assessed with the IL-1 receptor antagonist anakinra (10 mg/(kg·d), starting 24 hours post-MI). RESULTS: In vivo and ex vivo molecular imaging showed reduced myocardial inflammation after a 4-day course of anakinra treatment, despite no change in infarct size. At day 5 post-MI, high-speed optical mapping of transmembrane potential and intracellular Ca2+ in isolated hearts revealed that IL-1β inhibition improved conduction velocity, reduced action potential duration dispersion, improved intracellular Ca2+ handling, decreased transmembrane potential and Ca2+ alternans magnitude, and reduced spontaneous and inducible ventricular arrhythmias. These functional improvements were linked to increased expression of connexin 43 and sarcoplasmic reticulum Ca2+-ATPase. CONCLUSION: This study revealed a novel mechanism for IL-1β in contributing to defective excitation-contraction coupling and arrhythmogenesis in the post-MI heart. Our results suggest that inhibition of IL-1 signaling post-MI may represent a novel antiarrhythmic therapy.
BACKGROUND: Interleukin 1β (IL-1β) is a key regulator of the inflammatory response after myocardial infarction (MI) by modulating immune cell recruitment, cytokine production, and extracellular matrix turnover. Elevated levels of IL-1β are associated with adverse remodeling, and inhibition of IL-1 signaling after MI results in improved contractile function. OBJECTIVE: The goal of this study was to determine whether IL-1 signaling also contributes to post-MI arrhythmogenesis. METHODS: MI was created in 2 murine models of elevated inflammation: atherosclerotic on the Western diet or wild-type with a subseptic dose of lipopolysaccharide. The role of IL-1β was assessed with the IL-1 receptor antagonist anakinra (10 mg/(kg·d), starting 24 hours post-MI). RESULTS: In vivo and ex vivo molecular imaging showed reduced myocardial inflammation after a 4-day course of anakinra treatment, despite no change in infarct size. At day 5 post-MI, high-speed optical mapping of transmembrane potential and intracellular Ca2+ in isolated hearts revealed that IL-1β inhibition improved conduction velocity, reduced action potential duration dispersion, improved intracellular Ca2+ handling, decreased transmembrane potential and Ca2+ alternans magnitude, and reduced spontaneous and inducible ventricular arrhythmias. These functional improvements were linked to increased expression of connexin 43 and sarcoplasmic reticulum Ca2+-ATPase. CONCLUSION: This study revealed a novel mechanism for IL-1β in contributing to defective excitation-contraction coupling and arrhythmogenesis in the post-MI heart. Our results suggest that inhibition of IL-1 signaling post-MI may represent a novel antiarrhythmic therapy.
Authors: Antonio Abbate; Benjamin W Van Tassell; Ignacio M Seropian; Stefano Toldo; Roshanak Robati; Amit Varma; Fadi N Salloum; Lisa Smithson; Charles A Dinarello Journal: Eur J Heart Fail Date: 2010-04 Impact factor: 15.534
Authors: S Ørn; T Ueland; C Manhenke; Ø Sandanger; K Godang; A Yndestad; T E Mollnes; K Dickstein; P Aukrust Journal: J Intern Med Date: 2012-02-26 Impact factor: 8.989
Authors: Hendrik B Sager; Timo Heidt; Maarten Hulsmans; Partha Dutta; Gabriel Courties; Matthew Sebas; Gregory R Wojtkiewicz; Benoit Tricot; Yoshiko Iwamoto; Yuan Sun; Ralph Weissleder; Peter Libby; Filip K Swirski; Matthias Nahrendorf Journal: Circulation Date: 2015-09-10 Impact factor: 29.690
Authors: Michael J Cutler; Xiaoping Wan; Bradley N Plummer; Haiyan Liu; Isabelle Deschenes; Kenneth R Laurita; Roger J Hajjar; David S Rosenbaum Journal: Circulation Date: 2012-09-27 Impact factor: 29.690
Authors: R T Gardner; L Wang; B T Lang; J M Cregg; C L Dunbar; W R Woodward; J Silver; C M Ripplinger; B A Habecker Journal: Nat Commun Date: 2015-02-02 Impact factor: 14.919
Authors: Merry L Lindsey; Mira Jung; Andriy Yabluchanskiy; Presley L Cannon; Rugmani Padmanabhan Iyer; Elizabeth R Flynn; Kristine Y DeLeon-Pennell; Fritz M Valerio; Courtney L Harrison; Crystal M Ripplinger; Michael E Hall; Yonggang Ma Journal: Cardiovasc Res Date: 2019-02-01 Impact factor: 10.787
Authors: Samantha D Francis Stuart; Lianguo Wang; William R Woodard; G Andre Ng; Beth A Habecker; Crystal M Ripplinger Journal: J Physiol Date: 2018-08-03 Impact factor: 5.182